Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)
Phase 4
Completed
- Conditions
- Vitiligo
- Interventions
- Drug: cold creamDrug: topical tacrolimus treatment
- Registration Number
- NCT01082393
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
We will investigate the process of vitiligo induction and the influence of different commonly used cream treatments on this process. Studies comparing different treatments for vitiligo in the induction stage of the disease are still missing. The study hypothesis = cream treatment can stop actively spreading vitiligo lesions during the early induction stage of the disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Male and female,
- Age 18-70 years,
- Extensive vitiligo (> 50% body surface area),
- Patients asking for depigmenting therapy,
- Not pregnant.
Exclusion Criteria
- Children,
- Non extensive vitiligo (< 50% boy surface area),
- Patients not asking for depigmenting therapies,
- Pregnant.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description cold cream cold cream - topical tacrolimus topical tacrolimus treatment - topical pimecrolimus topical pimecrolimus treatment - local steroids local mometasone furoate treatment -
- Primary Outcome Measures
Name Time Method percentage of skin pigmentation in the treated area after 1 day, 10 days, 30 days and 60 days digital image analysis system for surface measurement
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Ghent
🇧🇪Ghent, Belgium